Blue Cross Blue Shield · Tecartus · US health-plan appeal rights

Tecartus denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Tecartus denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Federal Employee Program Medical Policy — Brexucabtagene Autoleucel (Tecartus)

The Blue Cross Blue Shield angle on Tecartus

## Why BCBS Denies Tecartus as Duplicate Therapy — and How to Appeal

Tecartus (brexucabtagene autoleucel) is an FDA-approved CAR-T cell therapy for relapsed or refractory mantle cell lymphoma (MCL) and adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). A "duplicate therapy" denial from BCBS typically arises when the reviewer claims that another CAR-T product already authorized or administered — or another anti-lymphoma agent in the patient's recent treatment history — makes Tecartus duplicative. This denial is almost always incorrect as applied to Tecartus, whose approved indications are distinct from those of other CAR-T products.

## Why This Denial Is Appealable

Each FDA-approved CAR-T product has a distinct indication, distinct target-cell manufacturing, and distinct clinical evidence base. Tecartus is the only FDA-approved CAR-T for adult relapsed/refractory B-ALL and one of the specific agents listed by NCCN for relapsed/refractory MCL post-BTK inhibitor. A prior CAR-T product authorized for a different indication (e.g., a BCMA-directed product for myeloma) does not duplicate Tecartus in MCL or B-ALL. Even within the same indication, selecting Tecartus over another CD19-directed product is a clinically individualized decision the treating hematologist-oncologist makes based on indication fit, prior exposure, and patient factors — not a coverage exclusion. "Duplicate therapy" requires the insurer to demonstrate that the same therapeutic effect is already being provided by an active concurrent treatment, which is not the case here.

## Federal Appeal Framework

Internal appeal: File within 180 days. BCBS must decide within 30 days (pre-service) or 60 days (post-service).
Expedited appeal: CAR-T is time-sensitive — patients with aggressive lymphoma or B-ALL have limited treatment windows. Request expedited review (72 hours) citing clinical urgency.
External review (ACA §2719 / ERISA §503): After internal exhaustion, file for external review immediately. Independent reviewers — typically board-certified hematologist-oncologists — are not bound by BCBS's duplicate-therapy characterization. The ~4-month external-review window runs from the original denial.

## Documentation to Gather

1. Pathology and diagnosis: Biopsy report and immunohistochemistry confirming MCL (cyclin D1/SOX11, t(11;14)) or B-ALL (flow cytometry, cytogenetics, FISH, molecular markers). 2. Prior-therapy history: Dates, regimens, and treatment outcomes for all prior lines, including BTK inhibitor exposure for MCL or prior induction/salvage regimens for B-ALL. 3. Treating oncologist's medical-necessity letter: Explaining that Tecartus is not duplicative of any current or prior therapy, why this patient requires Tecartus specifically, and how the indication aligns with FDA labeling and applicable NCCN guidelines. 4. REMS and treatment-center documentation: Confirmation that Tecartus will be administered at a FACT-accredited, REMS-certified authorized treatment center (ATC). 5. Denial of duplicate-therapy basis: A written response addressing which specific concurrent therapy BCBS claims duplicates Tecartus and why that characterization is clinically incorrect.

## Criteria-Mapping Structure

Obtain BCBS's current CAR-T or hematologic malignancy medical policy and the Tecartus FDA-approved prescribing information. Map each element:

| Issue Raised in Denial | Appeal Response | |---|---| | Identity of allegedly duplicating therapy | Named therapy + why it does not duplicate Tecartus | | FDA indication for Tecartus | Confirmed diagnosis + prior-line requirement met | | Patient not receiving concurrent CAR-T | Chart documentation of treatment status | | NCCN guideline alignment | Treating oncologist letter citing applicable NCCN category | | FACT-accredited ATC | Treatment-center credential documentation |

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Tecartus

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.